Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal Supraventricular Tachycardia: FDA Prescription Drug User Fee Act target date is March 27, 2025; Launch in PSVT targeted for mid-2025. Etripamil for patients with atrial fibrillation with rapid ventricular rate: Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio